Irene Ruderman, Stephen G Holt, Geoffrey S Kirkland, Sophie Maslen, Carmel M Hawley, Veronica Oliver, Rathika Krishnasamy, Nicholas A Gray, Girish S Talaulikar, Craig L Nelson, Yogeshwar Rajaram, Hilton Gock, Eric Au, Grahame J Elder, Rahul Mainra, Nigel D Toussaint
BACKGROUND: Secondary hyperparathyroidism (SHPT) in chronic kidney disease is associated with cardiovascular and bone pathology. Measures to achieve parathyroid hormone (PTH) target values and control biochemical abnormalities associated with SHPT require complex therapies, and severe SHPT often requires parathyroidectomy or the calcimimetic cinacalcet. In Australia, cinacalcet was publicly funded for dialysis patients from 2009 to 2015 when funding was withdrawn following publication of the EVOLVE study, which resulted in most patients on cinacalcet ceasing therapy...
January 2019: Internal Medicine Journal